CompletedPHASE1, PHASE2NCT00372619
Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
Studying Acute biphenotypic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Children's Oncology Group
- Principal Investigator
- Bassem I. Razzouk, MDSt. Vincent Indianapolis Hospital
- Intervention
- clofarabine(drug)
- Enrollment
- 74 enrolled
- Eligibility
- 1-30 years · All sexes
- Timeline
- 2007 – 2012
Study locations (30)
- UAB Comprehensive Cancer Center, Birmingham, Alabama, United States
- Southern California Permanente Medical Group, Downey, California, United States
- Jonathan Jaques Children's Cancer Center at Miller Children's Hospital, Long Beach, California, United States
- Children's Hospital Central California, Madera, California, United States
- Children's Hospital of Orange County, Orange, California, United States
- Rady Children's Hospital - San Diego, San Diego, California, United States
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
- Children's Hospital Colorado Center for Cancer and Blood Disorders, Aurora, Colorado, United States
- Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States
- Lombardi Comprehensive Cancer Center at Georgetown University Medical Center, Washington D.C., District of Columbia, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- Lee Cancer Care of Lee Memorial Health System, Fort Myers, Florida, United States
- Nemours Children's Clinic, Jacksonville, Florida, United States
- Nemours Children's Clinic - Orlando, Orlando, Florida, United States
- Nemours Children's Clinic - Pensacola, Pensacola, Florida, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00372619 on ClinicalTrials.govOther trials for Acute biphenotypic leukemia
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE2NCT07517510HVA in the Treatment of Mixed-Phenotype Acute Leukemia(MPAL).Guangdong Second Provincial General Hospital
- RECRUITINGPHASE1, PHASE2NCT07356154A Study of Revumenib and Mezigdomide in People With LeukemiaMemorial Sloan Kettering Cancer Center
- RECRUITINGNCT07537738Leukemia Stem Cell-based Assay to Predict Relapse and Survival in Patients With Acute Myeloid LeukemiaPeking University People's Hospital
- RECRUITINGPHASE1, PHASE2NCT05589896A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic MalignanciesOssium Health, Inc.
- RECRUITINGNANCT05794880MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG DosingMedical College of Wisconsin
- ACTIVE NOT RECRUITINGPHASE2NCT03399773Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic SyndromesFred Hutchinson Cancer Center
- RECRUITINGPHASE1, PHASE2NCT04797767Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid NeoplasmsUniversity of Washington
- ACTIVE NOT RECRUITINGPHASE2NCT04975919Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaM.D. Anderson Cancer Center